Third, there are varying estimates of the prevalence of anti-Ro52 in healthy individuals, with the highest estimate approximately 12% based on a study of 100 subjects [40], and we are unable to provide a true estimate of the prevalence of anti-Ro52 in patients with ILD to determine how this compares to that found in healthy controls. This evidence concerns the gene TRIM21 and interstitial lung disease.